The Venture Codex

Participated · Series A · Jun 2025

Autonomize AI offers an Agentic AI Orchestration platform with pre-trained, ready-to-deploy AI agents that coordinate as intelligent copilots across regulated healthcare workflows. The platform is healthcare-native, emphasizing explainability, human-in-the-loop workflows, and enterprise-wide orchestration rather than generic generative AI. Its agents address use cases such as care management, utilization management, benefits checks, and chart reviews, and are reported to deliver measurable operational impact at scale. Reported operating metrics include 36,000 clinical hours saved per month, 100,000+ automated care plans created monthly, and up to 50% faster decisions for prior authorizations and claims. Customers include Top 20 Pharmaceuticals, Fortune 100 healthcare enterprises, and life sciences companies. The company says it will use new funding to scale the platform and further rewire healthcare operations to reduce clinician burden and improve patient outcomes. Autonomize AI provides a secure, cloud-based AI platform optimized for healthcare and life sciences that ingests multi-modal and unstructured medical data using pre-trained medical LLMs. Its product suite includes Autonomize Pixel for clinical-trial workflows and patient matching, Autonomize Wizard for multi-modal chart insights, and generative-AI capabilities for conversational search and summarization of internal data. The platform supports fine-tuning on private data, deployment into virtual private clouds, and a privacy filter that anonymizes PII and PHI. Launched in 2022 and headquartered in Austin, Texas, the company emphasizes human-centered workflows to augment knowledge workers and improve operational efficiency. Customers report rapid ROI and efficiency gains—SubjectWell said medical-records review became ten times more efficient and accurate. Autonomize AI plans to use new funding to boost R&D and commercialization to drive down costs and accelerate adoption across healthcare organizations.

Participated · Equity · May 2025

Outcomes4Me is a Boston-based, direct-to-patient AI-driven platform that integrates clinical guidelines, genomic insights, clinical trial matching, medication and symptom tracking, and patient peer communities to help patients with cancer navigate care. The company uses patented technology and generates multimodal, patient-level datasets enriched at the drug level to deliver personalized, real-time treatment insights. Since its commercial launch in 2022, Outcomes4Me reports more than 280,000 cancer patients using its platform and an incredible revenue growth trajectory; seven of the top 10 global cancer pharmaceutical companies are among its customers. Outcomes4Me has raised $38M in total capital to date following a $21M round announced May 29, 2025. With the new funding the company plans to accelerate market penetration across additional cancer types and geographies, expand its AI capabilities, and strengthen collaborations with top-tier health systems and life sciences companies. It also intends to scale revenue streams through international expansion and outcomes-based evidence generation and real-world data insights to improve treatment and care. Outcomes4Me has developed an AI-powered patient empowerment platform that combines regulatory-grade, real-world data and patient experiences to generate insights for shared decision-making between patients and providers. The platform currently focuses on breast cancer and aims to improve care, accelerate research and achieve better outcomes. The company was co-founded in 2017 by Maya R. Said, Sc.D. (CEO) and Dr. Osama Rahma (Chief Medical Advisor); Sami Shalabi later joined as COO and brings prior Google leadership experience. Outcomes4Me plans to extend its platform beyond breast cancer to other cancers, grow its regulatory-grade dataset, and expand to more patients in Europe. The company raised $12M in a Series A to support those initiatives, indicating recent capital infusion to fund growth. Outcomes4Me offers a free mobile app and HIPAA-compliant platform that leverages artificial intelligence and machine learning to analyze medical records and provide patients with personalized, actionable information. The app is available on the Apple App Store and Google Play and surfaces resources traditionally targeted to physicians, including NCCN Guidelines and UpToDate drug information. Its technology has been applied to medical records from more than 700 institutions across the United States and Canada, and more than 10,000 breast cancer patients used the app in the past year. Co-founded by Maya R. Said, Sc.D., and Dr. Osama Rahma, the company aims to deliver timely, personalized guidance regardless of patients’ race, socioeconomic status, or location. Outcomes4Me recently added Sami Shalabi, formerly head of engineering and product development at Google, as chief operating officer. The company raised $4.7M to expand its reach to address cancers beyond breast cancer.

Led · Seed · Jul 2024

Endless Health is an Austin, TX-based end-to-end at-home testing and preventive medicine company that provides testing for key blood markers used to track risk of common causes of death. Led by CEO Cooper Galvin, it serves thousands of Americans and is building additional tools to support life-sciences research and evidence-based prevention programs. The company is concluding its first clinical trials later this summer for at-home and point-of-care medical devices that promote longevity. Endless Health is developing fully at-home clinical trial contracting services offering self-home collection kits, central lab services, patient recruitment, study monitoring, and compliant reporting. The company raised $4.5M in Seed funding to expand operations and business reach. Investors include Next Coast Ventures, Asset Management Ventures, and Antler Elevate, which increased its investment.

Participated · Seed · Aug 2023

Basys.ai offers a generative AI/deep learning engine that automates prior-authorization requests for drugs and procedures, claiming it can handle up to 90% of requests with high accuracy. The model was trained on longitudinal data from Joslin Diabetes Center and Mayo Clinic covering more than 10 million patients and does not require sensitive payer or provider data, which the company says shortens integration time from up to a year to weeks. Basys also automates encoding of payer policies, enabling it to plot timelines with health plans up to nine months faster than many competitors. The company launched commercially after initially selling to providers and had been generating revenue before pivoting its go-to-market to health insurance companies. It is initiating pilots with two large payers in Massachusetts and Minnesota and is working to capture patient outcomes such as reduced readmission rates and slowed disease progression. Basys.ai was founded in early 2022 by Amber Nigam and Jie Sun, who met in Harvard’s health data science program.

Led · Series B · Oct 2022

SubjectWell is an audience engagement platform for healthcare that matches patients with chronic conditions to clinical trials and other new care options. It uses a direct-to-consumer approach and reports registering 250,000 new patients per month while saying it can engage the 96 percent of the population that has never participated in clinical research. SubjectWell now partners with 16 of the top 20 pharmaceutical companies and has expanded into oncology, recruiting for non-small cell lung cancer and breast cancer studies. Revenue has grown 800 percent over the past two years, and the company says it is poised to double revenue again in the next 12 months. The platform aims to accelerate clinical trial enrollment timelines, support cancer research, and increase awareness and engagement for post-approval treatments through new service offerings. SubjectWell plans to use its scale and media-channel patient aggregation to extend awareness initiatives and commercial support for pharmaceutical customers. SubjectWell operates a risk-free clinical trials marketplace that connects prospective patients with available clinical studies. The platform’s core product is a single marketplace to build awareness and increase participation in clinical research by matching patients to trials. SubjectWell uses a performance-based pricing model and is compensated only for patients who randomize into studies. The company says hundreds of studies are already recruiting through its marketplace. The recent funding will support international expansion beyond North America into Europe, South America, and the United Kingdom. SubjectWell is headquartered in Austin, Texas and aims to broaden its patient pool and accelerate study enrollment.